SHERBROOKE, Québec (March 16, 2021)—Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.
Read MoreOTTAWA, ON, March 16, 2021 /CNW/ - Canadians have demonstrated a remarkable ability to mobilize in response to the COVID–19 pandemic. Companies in the biomanufacturing space from coast to coast to coast have answered the call, and the government wants to recognize their work. To date, the Government of Canada has made investments of approximately $1 billion to advance industrial research and development in vaccines and pharmaceuticals, as well as biomanufacturing capacity. We will continue to partner with Canadian industry and businesses to protect Canadians from COVID-19 while building new biomanufacturing capacity as part of our recovery plan.
Read MoreMONTREAL, March 16, 2021 /CNW/ - Amgen announced today that it has entered into a multi-year partnership with Mila – Quebec Artificial Intelligence Institute. One of the world's leading biotechnology companies, Amgen uses cutting-edge science and technology to discover and develop innovative therapeutics, and AI is currently deployed in several of its R&D and manufacturing activities. This new partnership will permit Amgen to expand its knowledge of AI and deep learning by interacting and engaging with experts in Mila's unique ecosystem, both virtually and (eventually) on the Mila campus in Montreal. This announcement was made during Effervescence 2021, an international virtual gathering of scientists, entrepreneurs and industry professionals from the life sciences and health technology sectors in the presence of the Quebec Minister of Economy and Innovation, Pierre Fitzgibbon.
Read MoreTORONTO, March 15, 2021 /CNW/ - Eli Lilly and Company recently announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with COVID-19. These results provide additional efficacy and safety data that support the use of the dose recently granted both Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) and a positive scientific opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Read MoreMONTREAL, Feb. 17, 2021 /CNW Telbec/ - Quebec welcomes a new player in its innovative ecosystem with the launch of Boreal Ventures, the first venture capital fund dedicated to high-tech ("deep tech") companies in Quebec. Created in partnership with Centech, a Montreal-based incubator specializing in technology, this fund will support the development of companies in the pre-seed and seed stages in science and engineering. With an initial investment capital of $26 million, Boreal Ventures will support companies that emerge from Centech and Quebec's innovative ecosystem. The start-ups targeted by this new fund operate in applied science (deep tech) sectors such as artificial intelligence, medical technologies, industry 4.0, and connected objects.
Read MoreMONTRÉAL, Feb. 4, 2021 /CNW Telbec/ - As part of its strategy to support Québec's life sciences sector through well-performing specialized funds, the Fonds de solidarité FTQ ("Fonds") is investing US$17.7 million (C$22.5 million) in Lumira IV. Over the years, Lumira has invested in Québec companies such as enGene, Kisoji, Opsens and IMV.
Read MoreMontreal, Canada – February 4, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.
Read MoreNexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany.
Read MoreThe latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020, with cancer treatments representing one third (35%) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the pipeline, at 13%, and are expected to grow in importance in response to the COVID-19 pandemic.
Read MoreInnodem Neurosciences, a Montreal-based company, has closed a Series A financing round led by Morningside Ventures to support the development and commercialization of its proprietary, patented, digital biomarking technology of neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's disease, Parkinson's disease and related disorders, Frontotemporal Dementia and related disorders and Cancer-Related Cognitive Impairment ("chemo brain").
Read MoreBamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events") in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, Eli Lilly and Company (NYSE: LLY) announced.
Read MoreFORUS Therapeutics launches today, bringing a new pharmaceutical company onto the Canadian landscape. With a highly-experienced and proven team, an FDA-approved product already in its pipeline, and significant financial investment secured, the Toronto-based company looks to bring innovative cancer therapies to Canadian patients, new treatment tools for caregivers and physicians, and in the future, be a preferred partner for emerging Canadian-based research companies.
Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events") in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, Eli Lilly and Company (NYSE: LLY) announced.
Read MoreNovartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Zolgensma® (onasemnogene abeparvovec) an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and 3 or fewer copies of SMN2 gene; or infantile-onset SMA1.
Read MoreThe Canadian IPO market surprised in 2020 with proceeds in excess of $5 billion for the year, despite fewer new issuances than in previous years. This is five times the value of offerings completed in 2019. Despite a year marked by the COVID-19 pandemic and amid economic uncertainty, the capital markets were extremely robust.
Read MoreLiminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that the Company's wholly-owned subsidiary, Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration ("FDA") approval for its plasma collection center located in Amherst, NY.
Read MoreIncyte (NASDAQ: INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody.
Read MoreadMare BioInnovations, Canada's global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company developing novel next-generation targeted alpha therapies (TATs) for patients with relapsed, refractory and metastatic cancers.
Read MoreThe Fonds de solidarité FTQ ( "Fonds") is renewing its partnership with life sciences venture capital firm Forbion by investing €15 million (C$23 million) in Forbion Capital Fund V.
Read MoreadMare BioInnovations, Canada's global life sciences venture, is proud to announce the start-ups selected to join its new acceleration program for Quebec emerging companies.
Read More
